The Asia Pacific is the largest geographic market and it is expected to be the largest revenue generator during the forecast period. The Asia Pacific breast reconstruction market is expected to grow with CAGR of 3.9% to US$ 132.3 Mn 2025 from US$ 98.2 Mn in 2017. Factors such as, presence of large pool of breast cancer patients and increasing awareness on breast reconstruction procedures, are likely to grow the market in the forecast period.
The global breast reconstruction market is expected to reach US$ 684.53 Mn in 2025 from US$ 526.47 Mn in 2017. The market is estimated to grow with a CAGR of 3.5% from 2018-2025, owing to factors such as rising prevalence of breast cancer, increase in number of regulatory approvals & new product launches, and growing number of breast reconstruction procedures.
Get sample PDF copy at: https://www.theinsightpartners.com/sample/TIPHE100001298/
- Allergan Plc
- Mentor Worldwide LLC
- Sientra Inc.
- GC Aesthetics PLC
- POLYTECH Health & Aesthetics GmbH
- Hansbiomed Co. Ltd.
- Ideal Implant Incorporated
- Guangzhou Wanhe Plastic Materials Co., Ltd.
- Establishment Labs S.A.
- Groupe Sebbin SAS
The global breast reconstruction market, based on the placement was segmented into dual-plane insertion, subglandular insertion and submuscular insertion. In 2017, the dual-plane insertion segment held the largest share of the market, based on the placement. In addition, the segment also grows at the fastest rate during the coming years.
Patients undergoing unilateral or bilateral mastectomy procedures usually opt breast reconstruction for various reasons that are inclusive of regaining the original shape of the breasts, improve aesthetic appeal and others. Thus, it is important for the market players to come up with innovative products that will boost the adoption of this procedure at marginal rates. Tissue expander is one such innovation in the direction for easing the task of surgeons and improving the performance of the reconstruction procedure. In December 2016, the U.S. Food and Drug Administration (FDA) approved marketing for a tissue expander named AeroForm by AirXpanders, which is a needle-free alternative for patients undergoing breast reconstruction procedure. Thus, market players capitalizing and investing in similar innovative technologies to come up with breakthrough products can lead in high revenue generation and marginal profits.
Although breast reconstruction does not possess any risk of breast cancer recurrence, a large number of post-operative complications are associated with it. These complications include occurrence of a mass or lump within the reconstructed breast due to the accumulation of clear fluid, pooling of blood near the reconstructed breast, infections, extrusion of the implant, blood clots, implant rupture, obesity, formation of hard scar tissue around the implant, diabetes. In addition, the breast implants also can cause a possible risk of developing anaplastic large cell lymphoma (ALCL) which refers to a rare form of immune system cancer. For instance, the U.S. FDA as of September 2017 received 414 medical devices reports (MDRs) on Breast Implants associated Anaplastic Large Cell Lymphoma (BIA-ALCL). The risk of breast reconstruction failure increases even more after radiation therapy. For instance, according to a review article published by PRMA Plastic Surgery, about 1 in 3 breast implant reconstruction procedures fail after radiation therapy among breast cancer patients. Moreover, the implants also cause various complications if not removed or replaced at appropriate time. In case of autologous reconstruction, necrosis of the transferred tissues may cause serious medical complications. Thus, the aforementioned factors are expected to hamper the growth of breast reconstruction market at certain extent.
Although breast reconstruction does not possess any risk of breast cancer recurrence, a large number of post-operative complications are associated with it. These complications include occurrence of a mass or lump within the reconstructed breast due to the accumulation of clear fluid, pooling of blood near the reconstructed breast, infections, extrusion of the implant, blood clots, implant rupture, obesity, formation of hard scar tissue around the implant, diabetes. In addition, the breast implants also can cause a possible risk of developing anaplastic large cell lymphoma (ALCL) which refers to a rare form of immune system cancer.
Partnership/acquisition, and product launch & approvals were observed as the most adopted strategy in global breast reconstruction industry. Few of the acquisition, partnership, product launches and approvals made by the players in the market are listed below:
2018: Sientra Inc. received approval from U.S. Food and Drug Administration (FDA) for the PMA supplement permitting the commercialization of OPUS-branded breast implant products which are manufactured by Vesta, a Lubrizol LifeSciences company.
2017: Allergan acquired Keller Medical, Inc. a medical device company which develops Keller Funnel.
2016: GC Aesthetics launched new products in Brazil Market. The company introduced Matrix and IMPLEO in Brazil market. Nagor (UK) subsidiary of GC Aesthetics IMPLEO is produced and Eurosilicone (France) where The Matrix is developed.
2015: Mentor introduced MENTOR ARTOURA breast tissue expander which is the first and only tissue expander capable of providing precisely controlled pocket formation for predictable expansion outcomes.
Purchase Copy of This Report at: https://www.theinsightpartners.com/buy/TIPHE100001298/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.
Email: [email protected]